CHALLENGES AND OPORTUNITIES WITH NATIONAL STUDIES IN NIGERIA

DR OLAYINKA O.OGUNLEYE

Senior Lecturer and Consultant Physician/Clinical Pharmacologist

LASUCOM/LASUTH, IKEJA, LAGOS, NIGERIA

• Total population in Nigeria estimated at 178.5 million people in 2014


– 45.2 million in 1960 at Independence

- Nigerian population represents 2.35 percent of the world's population
 - Arguably 1 person in every 43 people on the planet is a resident of Nigeria

- Per capita income of about USD 2,722 per year
- The country is divided into six geo-political zones administratively
- Comprises of 36 states and The Federal Capital Territory and a total of 774 Local Government Areas
- At least 37 major cities and several relatively large rural communities

- Currently faced with lots of socioeconomic challenges
 - Inflation rate highest in 7 years
 - Shrinking economy
 - Terrorism and Insurgency
 - Unemployment rate on the rise

Pharmaceutical Management Cycle



- Each of the aspects of the Pharmaceutical Management Cycle in Nigeria has challenges and therefore presents lots of opportunities for research driven interventions
 - Selection
 - Procurement
 - Distribution
 - Use(Prescribers/Consumers)
 - Policy/Regulation/Laws
 - Management Support

Nigerian Pharmaceutical Market

- Pharmaceutical market is anticipated to grow more than double its current size to USD 1.3 trillion in 2020
- Pharmaceutical import in Nigeria put at a value of USD 481million in 2013 and are expected to reach USD 789 million in 2018 (10.4% increase).

- Currently, no national distributor to distribute drugs throughout the country
 - About 300 drug importers made up of financially strong distributors
 - Floods the products in the wholesale market for the retailers to buy
 - They also supply directly to big retailers and hospitals
 - Second model: Many foreign manufacturing companies get the registration through the wholesale importers and retailers buy from them

 The third model: The wholesalers(importers) get the registration on its own name and get the product contract manufactured from the manufacturer and then sell to other wholesaler and then retailers in that order.

Unaffordable Medicines

- Pricing Structure
 - Drug prices in Nigeria are set mostly by market forces, with government tariffs, taxes and distribution mark-ups accounting for a significant proportion of the final price
 - Prices therefore vary between outlets, facilities and types of products
 - Generic drugs are priced much higher than their equivalents in neighboring countries

- Findings of a 2004 survey on medicine prices in Nigeria carried out by the FMOH/WHO/DFID/EU/HAI:
 - Medicines were unaffordable to about 90% of Nigerians who lived below the income level of US\$2 per day
 - Patients paid between 2-64% times international reference prices for medicines in the various health facilities surveyed

- Medicines were more expensive in the private health sectors
- Wide variability of prices for the same medicines between facilities, sectors and different types of the same product
- The prices of procured medicines was 2 to 38 times international prices in the public owned central stores studied
- The Non-Governmental Organisation owned central stores recorded a 20 times less costs.

- Poor budgetary allocation to health in the face of rising disease burden (Communicable and Non-Communicable)
- Public expenditure on health in Nigeria accounts for only about 20 to 30% of the total health expenditure, while the remaining 70 to 80% is derived from private expenditures
- The private expenditure expenses is constituted mostly by 'out of pocket' (OOP) expenditures.
- OOP spending on health care in Nigeria can be as high as 62% of the total healthcare expenditure.

Use of Medicines

- Lack of skills and knowledge
 - Lack of independent information such as clinical guidelines
 - Traditional pharmacology trainings seems to be more concentrated on 'theory' than 'practice'.
 - Therapeutics is rarely taught in medical schools/postgraduate training
 - Although pharmacology knowledge is acquired, practical prescribing skills remain weak

- Inappropriate unethical promotion of medicines by pharmaceutical companies.
 - Most prescribers get medicine information from pharmaceutical companies rather than independent sources such as clinical guidelines.
 - This often leads to overuse.

- Unrestricted availability of medicines.
 - Prescription medicines such as antibiotics, are freely available over-the-counter, unfortunately also in market places/motor parks.
 - This leads to overuse, inappropriate selfmedication and non-adherence to dosing regimes.
- Lack of Consumer Knowledge about Drugs



- Lack of coordinated national pharmaceutical policy
 - Lack of appropriate measures and infrastructure for monitoring and regulation of medicines use
 - Lack of appropriate training and supervision for prescribing health workers
- Non-Existence of DTCs across the nation
- Regulatory Activities (Not Too Successful Yet)

Access to medicines and RUD in Nigeria

- The first Nigerian National Medicine Policy (1996)
- Revision of the Policy (2005)
- Evaluation of the various aspects of the policy(2008)
 - Employed the WHO levels I and II facility survey tools
 - Carried out in 30 public health facilities and 30 private medicine outlets in 5 out of the 6 geopolitical zones of the country

Summary of Key findings of the 2008 Evaluation

- Most private medicine outlets engage the services of more untrained than trained staff
- Cost of medications in both public and private sectors were high and unaffordable to patients
- Availability of medicine was higher in private medicine outlets
- Most public health facilities had long stock out duration and did not keep adequate records

- Most of the public health facilities did not have EML, however most of the medicines prescribed were listed on the EML but not written in generic names
- Antibiotics and injection prescribing were high
- Private medicine outlets often sold prescription medicine to patients without a prescription
- Medicines were usually inappropriately labelled in both public and private outlets

Some Identified Areas of Strength/Promises

 Several professionals mostly physicians/clinical pharmacologists, pharmacists and public health physicians interested in DUR

making some efforts in this direction over the years

- MURIA-The Nigerian Group/ Supports from International Partners and Colleagues
- The vast areas of needs available for research and interventions.
- Prescription Skills Training/Assessment IN VIEW

Challenges

- Need for proper coordination of research activities among professionals sharing similar interests
 - The potential impacts of DUR on health care delivery system in Nigeria is yet to be seen
- Knowledge gaps in methodologies of DUR still exists
- Lack of funding for research
- Research Tools Needs.
- Inter-professional disharmony in Nigerian Health Sector/ Pronounced in the Public Sector.

- Lack of Computerized database/s
 - Available data were manually generated
 - Not been able to link Drug Utilization to Diagnosis
 - The National Health Insurance Scheme could have been helpful in this respect but:
 - Covers less than 10% of the population presently
 - Lack of adequate drug utilization data is prevalent

On-Going Research Activities/Planned National Studies

- Patterns of Utilization of Antibiotics in Nigeria: A pharmacoepidemiological and pharmacoeconomic analysis (including Point Prevalence Studies)
 - Protocol Developed
 - Ethical Approval Sought
 - Funding Application Submitted to The Tertiary Education Trust Fund (TETFUND), Nigeria
 - Federal Ministry of Health being engaged
- Patterns of Utilization of Antihypertensive and Statin Drugs in Nigeria: A pharmacoepidemiological and pharmacoeconomic analysis – IN VIEW
- Assessment of Availability and Functions of Drug and Therapeutic Committees in Nigeria – ON GOING

Conclusion

- Diverse Challenges exists all around each of the aspects of the Pharmaceutical Management Cycle in Nigeria presenting opportunities for research driven interventions
- There is the need for concerted efforts towards overcoming the identified challenges and making the most use of the opportunities.

